| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 1,571 | 1,664 | 1,697 | 1,783 | 1,839 | 2,038 | 1,959 | 2,121 | 2,104 |
| Expenses | 1,261 | 1,337 | 1,381 | 1,460 | 1,479 | 1,621 | 1,601 | 1,724 | 1,687 |
| EBITDA | 311 | 327 | 316 | 323 | 360 | 417 | 359 | 397 | 417 |
| Operating Profit % | 19 % | 20 % | 17 % | 18 % | 19 % | 19 % | 18 % | 19 % | 20 % |
| Depreciation | 67 | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 100 |
| Interest | 52 | 59 | 61 | 66 | 59 | 46 | 32 | 39 | 27 |
| Profit Before Tax | 191 | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 |
| Tax | 50 | 52 | 51 | 46 | 55 | 72 | 74 | 63 | 76 |
| Net Profit | 141 | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 |
| EPS in ₹ | 7.21 | 7.70 | 6.27 | 6.36 | 7.95 | 10.23 | 8.12 | 9.97 | 10.92 |
Emcure Pharmaceuticals
Emcure Pharmaceuticals
1,284.20
-41.60
(-3.14%)
Market Cap
24,336.70 Cr
EPS
36.43
PE Ratio
32.30
Dividend Yield
0.23 %
Industry
Healthcare52 Week High
1,532.95
52 Week Low
889.00
PB Ratio
5.47
Debt to Equity
0.45
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
Emcure Pharmaceuticals Approves Incorporation of Wholly-Owned Subsidiary Emcure WellnessSep 06, 2025
Emcure Pharmaceuticals' Board of Directors approved the incorporation of a wholly-owned subsidiary named Emcure Wellness Private Limited in Pune, Maharashtra. The new entity will have an authorized share capital of Rs. 10 crores and initial paid-up capital of Rs. 1 lakh. The subsidiary will operate in the pharmaceuticals industry to manufacture, promote, sell and distribute pharmaceuticals and related products. Emcure will subscribe to 100% of the initial share capital through cash consideration at face value of Rs. 10 per share.
Emcure Pharmaceuticals Reports Strong Q1 FY26 Results with 15.7% Revenue Growth and Record Quarterly ProfitAug 13, 2025
Emcure Pharmaceuticals delivered robust quarterly results with revenue growing 15.7% year-on-year to INR 2,101 crores. The company reported its highest quarterly profit of INR 215 crores, representing 41% growth. EBITDA increased 20% to INR 404 crores with margins at 19.2%. Domestic business grew 9.4% to INR 995 crores, while international markets expanded 22% to INR 1,106 crores. Emerging markets showed impressive 42% growth to INR 360 crores. The company expanded its partnership with Sanofi, adding diabetes portfolio brands Amaryl and Cetapin worth INR 200 crores annually. Management outlined a 5-year vision focusing on innovation, partnerships, and geographical expansion, targeting growth 2% above industry rates. Key product developments include ongoing trials for Asparaginase and wet AMD treatments, with approvals expected this financial year. The company appointed R.S. Vasan as President - India business and remains insulated from US market risks with less than 3% exposure.
Emcure Pharma delivered robust quarterly results with revenue increasing to 21 billion rupees from 18.15 billion rupees in the same period last year. The pharmaceutical company's consolidated net profit grew significantly to 2.15 billion rupees compared to 1.4 billion rupees year-over-year. EBITDA rose to 4.2 billion rupees from 3.37 billion rupees, while EBITDA margin improved to 19.8% from 18.6% in the corresponding quarter of the previous year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
18.67 %
Net Income Growth
34.10 %
Cash Flow Change
-22.38 %
ROE
-9.82 %
ROCE
-1.72 %
EBITDA Margin (Avg.)
0.99 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 5,247 | 5,644 | 6,004 | 6,807 | 6,064 | 6,673 | 7,806 | 8,233 |
| Fixed Assets | 2,049 | 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | 3,197 |
| Current Assets | 2,335 | 2,453 | 2,703 | 3,718 | 3,424 | 3,836 | 4,260 | 4,556 |
| Capital Work in Progress | 531 | 581 | 485 | 302 | 320 | 411 | 159 | 177 |
| Investments | 0 | 0 | 0 | 0 | 25 | 25 | 318 | 95 |
| Other Assets | 2,667 | 2,817 | 3,137 | 4,318 | 3,674 | 4,089 | 4,204 | 4,763 |
| Total Liabilities | 5,247 | 5,644 | 6,004 | 6,807 | 6,064 | 6,673 | 7,806 | 8,233 |
| Current Liabilities | 2,336 | 2,543 | 2,920 | 3,408 | 2,965 | 3,019 | 3,211 | 2,668 |
| Non Current Liabilities | 1,157 | 1,201 | 1,100 | 1,031 | 985 | 1,004 | 1,474 | 923 |
| Total Equity | 1,755 | 1,900 | 1,984 | 2,368 | 2,114 | 2,650 | 3,122 | 4,642 |
| Reserve & Surplus | 1,520 | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 | 4,257 |
| Share Capital | 181 | 181 | 181 | 181 | 181 | 181 | 181 | 190 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -700 | 32 | 259 | 42 | 134 | 219 | -58 |
| Investing Activities | -409 | -168 | -257 | -575 | -468 | -715 | -96 |
| Operating Activities | 444 | 500 | 704 | 768 | 747 | 1,097 | 852 |
| Financing Activities | -735 | -301 | -189 | -152 | -145 | -164 | -814 |
Share Holding
| % Holding | Jul 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 78.08 % | 78.08 % | 77.94 % | 77.92 % | 77.91 % |
| FIIs | 1.76 % | 2.91 % | 3.05 % | 3.07 % | 2.86 % |
| DIIs | 3.34 % | 3.96 % | 3.87 % | 3.44 % | 2.84 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.73 % | 5.00 % | 5.14 % | 5.51 % | 5.95 % |
| Others | 9.10 % | 10.04 % | 10.00 % | 10.06 % | 10.44 % |
| No of Share Holders | 4,98,006 | 1,52,914 | 1,43,449 | 1,39,671 | 1,33,549 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 3 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.23 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 1,406.40 | 1,444.25 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 1,345.75 | 1,249.80 |
| 22 May 2025 | Quarterly Result Announcement | NA | 22 May 2025 | 1,036.35 | 1,073.60 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 1,405.55 | 1,421.25 |
| 14 Aug 2025 |  Dividend | ₹ 3.00 /share | 14 Aug 2025 | 1,073.60 | 1,453.80 |
| 28 Aug 2025 |  Annual General Meeting | NA | 28 Aug 2025 | 1,408.15 | 1,468.60 |
Announcements
Closure of Trading Window
1 day ago
1 day agoUpdate On Re-Appointment Of Dr. Mukund Gurjar As A Whole-Time Director And Appointment Of Secretarial Auditor Of The Company.Aug 29, 2025
Aug 29, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 29, 2025
Aug 29, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Intimation Under Regulation 30 And 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 About Dispatch Of Letters To The Members Whose E-Mail Addresses Are Not Registered With The Company/ Depository Participants.Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 07, 2025
Aug 07, 2025Outcome Of The Board Meeting Held On August 07 2025 To Approve The Unaudited Financial Results (Consolidated And Standalone) For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On August 07 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 03, 2025
Aug 03, 2025Intimation Of Notice Of The 44Th Annual General Meeting Of Emcure Pharmaceuticals Limited To Be Held On Thursday August 28 2025Aug 02, 2025
Aug 02, 2025Reg. 34 (1) Annual Report.Aug 02, 2025
Aug 02, 2025Intimation Of The 44Th AGM And Record Date For Final Dividend For The Financial Year Ended March 31 2025.Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 28, 2025
Jul 28, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2025.Jul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 14, 2025
Jul 14, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At Our Manufacturing Facility (Oncology) Located At Sanand Ahmedabad Gujarat India.Jul 09, 2025
Jul 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 04, 2025
Jul 04, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Submission Of Application For Seeking Re-Classification From The Promoter And Promoter Group Category To Public CategoryJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJun 25, 2025
Jun 25, 2025Disclosure Of Key Performance Indicators (Kpis) Under The SEBI (Issue Of Capital And Disclosure Requirements) Regulations 2018Jun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jun 21, 2025
Jun 21, 2025Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Outcome Of The Meeting Of The Board Of Directors Considering Requests For Re-Classification From The Promoter And Promoter Group Category To PJun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 21, 2025
Jun 21, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On June 21 2025Jun 21, 2025
Jun 21, 2025Outcome Of Board Meeting Held On June 21 2025Jun 21, 2025
Jun 21, 2025Intimation Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Requests For Re-Classification From The Promoter And Promoter Group Category To Public CategoryJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 12, 2025
Jun 12, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Clarification On Volume Movement LetterMay 27, 2025
May 27, 2025Clarification sought from Emcure Pharmaceuticals LtdMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-AcquisitionMay 22, 2025
May 22, 2025Appointment Of Secretarial AuditorMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 22, 2025
May 22, 2025Audited Financial Results For The Quarter And Year Ended March 31 2025May 22, 2025
May 22, 2025Corporate Action-Board approves DividendMay 22, 2025
May 22, 2025Technical Indicators
RSI(14)
Neutral 31.46
ATR(14)
Volatile 36.65
STOCH(9,6)
Neutral 20.18
STOCH RSI(14)
Neutral 21.54
MACD(12,26)
Bearish -5.90
ADX(14)
Strong Trend 29.21
UO(9)
Bearish 42.25
ROC(12)
Downtrend And Accelerating -5.73
WillR(14)
Oversold -93.33
Mutual Fund Holdings
DSP Aggressive Hybrid Fund Direct-Growth 
UTI Healthcare Fund Direct-Growth 
Edelweiss Recently Listed IPO Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Bajaj Finserv Large and Mid Cap Fund Direct-Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Quant Fund Direct-Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Groww Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes in orals, injectables, and biotherapeutics, covering areas such as gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related, and oncology treatments. The company has a portfolio of differentiated products, including chiral molecules, complex APIs, biologics, and novel drug delivery systems. Emcure has commercialized six in-house manufactured biologics and holds patents for specific treatments. The company expanded through mergers, acquisitions, and establishment of new facilities over the years. In July 2024, Emcure launched an Initial Public Offer.
Listing Date
10 Jul, 2024(1 Years,
18 days)
Website
Chairperson NameBerjis M Desai
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
